AZTRAzitra, Inc.

NYSE azitrainc.com


$ 2.36 $ -0.64 (-21.33 %)    

Tuesday, 02-Jul-2024 12:14:28 EDT
QQQ $ 482.96 $ 3.07 (0.64 %)
DIA $ 391.00 $ 0.16 (0.04 %)
SPY $ 545.54 $ 1.80 (0.33 %)
TLT $ 90.15 $ -0.51 (-0.57 %)
GLD $ 214.73 $ -0.54 (-0.25 %)
$ 3.4
$ 3.00
$ 0.00 x 0
$ 2.36 x 200
$ 2.22 - $ 3.01
$ 2.52 - $ 129.80
155,076
na
2.29M
$ -28.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-15-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-azitra-aztr-shares-are-down-29-today

Azitra shares are trading lower by 29% during Tuesday's session. The company announced a mixed shelf offering of up to $50 ...

 on-monday-july-1-2024-azitra-filed-for-mixed-shelf-offering-of-up-to-50m

- SEC Filing

 azitra-announces-1-for-30-reverse-stock-split-will-become-effective-on-july-1-2024

Common Stock Will Begin Trading on a Split-Adjusted Basis on July 1, 2024

 azitra-received-notice-of-allowance-for-us-patent-application-titled-therapeutic-treatment-of-skin-disease-with-recombinant-commensal-skin-microorganisms

https://patentcenter.uspto.gov/applications/16890552/ifw/docs

 azitra-presents-preclinical-data-from-atr-04-at-society-of-investigative-dermatology-annual-meeting

ATR-04 is in development for epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approxim...

 azitra-reports-preclinical-data-of-atr-12-and-clinical-design-on-netherton-syndrome-at-asgct-annual-meeting

ATR-12 has nanomolar inhibition of key protease in vitro that drives Netherton syndromeTopical application of ATR-12 to ex vivo...

 azitra-inc-announces-preclinical-data-from-the-cos-platform-and-pipeline-on-friday-may-10-2024-in-two-oral-sessions-entitled-engineered-staphylococcus-epidermidis-as-a-protein-delivery-system-for-treating-skin-diseases-and-staphylococcus-epidermidis-strain-expressing-lekti-d6-atr12-351-for-netherton-syndrome

Azitra will present two oral presentations at ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 r...